AGOURA HILLS, Calif.,
June 24, 2013 /PRNewswire/
-- Biozoom (OTC QB: BIZM) creator of the world's first of its
kind portable, handheld device for real-time biofeedback, announced
today that the device has entered commercial production. "The
Biozoom scanner has captured the attention of so many organizations
that production has moved from prototype to commercial scale," said
Biozoom CTO, Dr. Wolfgang Kocher.
The first shipment of scanners is expected to arrive in September.
"They will be used to extend our test marketing with key
commercial, healthcare and governmental entities."
The Biozoom scanner non-invasively measures and analyzes the
biomarkers critical to understanding, managing and improving a
user's health and wellness. The prototype units have been validated
in clinical trials and used at respected European institutions. The
first commercially produced scanners are expected to be used for
large-scale studies by major multinational cosmetics and consumer
goods producers, as well as large employers.
A portion of the first shipment will be dedicated to market
testing in the United States,
where health and wellness represent a $150
billion opportunity. "People everywhere want to live longer
and healthier lives. A recent study by the Consumer Electronics
Association indicated that 55% of online consumers in the US used
some form of fitness electronics last year, and 37% anticipate
buying a wellness related device this year," said Dr. Kocher.
Biozoom's innovation has been the successful miniaturization of
reflection spectroscopy. The development of the biofeedback scanner
has its roots in patented optics produced by Carl Zeiss, which overcome the challenges of
portable, handheld spectroscopy. At the press of a button, the
transdermal scanner collects and sends spectroscopic data to
Biozoom's servers, which instantly return both results and wellness
support coaching to the user.
"We have reached an exciting milestone," said CEO Hardy Hoheisel. "The first commercially produced
units will include all of the patented components and will prove
the feasibility of low-cost mass production."
Because the Biozoom scanner measures anti-aging factors
including skin moisture and nutritional absorption, "it is of great
interest to the cosmetics industry," said Dr. Kocher. "At the same
time, the scanner gives new insight into the overall health and
wellbeing of users by measuring antioxidant levels, stress
responses and much more. Several large organizations have expressed
interest in using the scanner to understand and support the health
of their employees. By focusing on wellness and disease
prevention, they can use Biozoom to help drive down healthcare
costs and absenteeism due to preventable
illness."
About Biozoom
Biozoom is an innovative technology
development company, specializing in the commercialization of our
advances in mobile spectroscopy. Our intellectual property
portfolio and ongoing research are positioned to apply Biozoom's
technology breakthroughs to a wide range of markets. Our first
consumer product, the Biozoom scanner, gives people the feedback
they need to manage their health, wellness and fitness on
demand. Tested in leading health institutions, our scanner is
the first of its kind—a handheld, transdermal device for
measuring biomarkers, including antioxidant levels, at the click of
a button. Scan results—and customized wellness coaching based on
those biomarkers—are sent instantly to a smartphone or online
account. The scanner will enable leaders in the health and
wellness industry to create new levels of customer loyalty and
revenues as a result. For more information, visit
www.biozoom.net.
Disclaimer
This press release contains
"forward-looking statements". Statements in this press release
which are not purely historical are forward-looking statements and
include any statements regarding beliefs, plans, expectations or
intentions regarding the future, and specifically references to
future potential purchase orders and re-orders from consumers and
distributors. The reader can identify these forward-looking
statements by forward-looking words such as "may," "will,"
"expect," "potential," "anticipate," "forecast," "believe,"
"estimate," "project," "plan," "continue" or similar words. The
reader should read statements that contain these words carefully
because they discuss future expectations, contain projections of
future results of operations or of financial condition, or state
other forward-looking information. Forward-looking statements
include, but are not limited to, statements regarding potential
products, customers, revenues, expansion efforts, and future plans
and objectives of Biozoom, Inc. ("Biozoom"). The risk factors
listed in our disclosure documents and the cautionary language
therein provide examples of risks, uncertainties and events that
may cause actual results to differ materially from the expectations
and projections described by Biozoom in its forward-looking
statements. Actual results relating to, among other things, product
launch, sales, customer acceptance and market share could differ
materially from those currently anticipated in such statements.
Factors affecting forward-looking statements include: consumer
preferences, competition from more established brands, ability to
develop market share; changes in the operating costs; changes in
economic conditions, foreign exchange and other financial markets;
changes of the interest rates on borrowings; changes in the
investments levels; litigation; legislation; environmental,
judicial, regulatory, political and competitive developments in
areas in which Biozoom operates; technological, mechanical and
operational difficulties encountered in connection with Biozoom's
development activities; and labor relation matters and costs. The
reader should refer to the risk disclosures set out in the periodic
reports and other disclosure documents filed by Biozoom from time
to time with the Securities and Exchange Commission and other
regulatory authorities.
SOURCE Biozoom, Inc.